Tower Research Capital (TRC)’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $163K | Buy |
7,773
+7,766
| +110,943% | +$175K | ﹤0.01% | 1785 |
|
|
2025
Q4 | $161 | Sell |
7
-1,958
| -100% | -$64.4K | ﹤0.01% | 5010 |
|
|
2025
Q3 | $59.1K | Buy |
1,965
+505
| +35% | +$15.1K | ﹤0.01% | 2398 |
|
|
2025
Q2 | $53.1K | Sell |
1,460
-1,090
| -43% | -$39.3K | ﹤0.01% | 2924 |
|
|
2025
Q1 | $92.3K | Sell |
2,550
-14,277
| -85% | -$594K | ﹤0.01% | 1814 |
|
|
2024
Q4 | $708K | Buy |
16,827
+15,974
| +1,873% | +$792K | 0.01% | 842 |
|
|
2024
Q3 | $47.4K | Sell |
853
-13,450
| -94% | -$685K | ﹤0.01% | 2746 |
|
|
2024
Q2 | $588K | Buy |
14,303
+12,841
| +878% | +$548K | 0.01% | 1204 |
|
|
2024
Q1 | $68.3K | Buy |
1,462
+84
| +6% | +$3.96K | ﹤0.01% | 2073 |
|
|
2023
Q4 | $65.9K | Sell |
1,378
-2,195
| -61% | -$85.1K | ﹤0.01% | 2948 |
|
|
2023
Q3 | $127K | Sell |
3,573
-13,196
| -79% | -$523K | ﹤0.01% | 1786 |
|
|
2023
Q2 | $774K | Buy |
16,769
+13,472
| +409% | +$625K | 0.03% | 677 |
|
|
2023
Q1 | $132K | Sell |
3,297
-6,614
| -67% | -$284K | ﹤0.01% | 1630 |
|
|
2022
Q4 | $459K | Buy |
9,911
+2,906
| +41% | +$114K | 0.02% | 756 |
|
|
2022
Q3 | $290K | Buy |
7,005
+1,703
| +32% | +$87.5K | ﹤0.01% | 1575 |
|
|
2022
Q2 | $317K | Buy |
5,302
+1,733
| +49% | +$107K | 0.01% | 1440 |
|
|
2022
Q1 | $260K | Buy |
3,569
+994
| +39% | +$69.2K | ﹤0.01% | 1553 |
|
|
2021
Q4 | $216K | Sell |
2,575
-946
| -27% | -$77K | ﹤0.01% | 1705 |
|
|
2021
Q3 | $317K | Sell |
3,521
-8,669
| -71% | -$784K | 0.01% | 1346 |
|
|
2021
Q2 | $1.16M | Buy |
12,190
+7,830
| +180% | +$816K | 0.03% | 556 |
|
|
2021
Q1 | $497K | Buy |
4,360
+1,201
| +38% | +$164K | 0.01% | 1247 |
|
|
2020
Q4 | $437K | Sell |
3,159
-1,881
| -37% | -$223K | 0.01% | 1092 |
|
|
2020
Q3 | $414K | Sell |
5,040
-1,900
| -27% | -$157K | ﹤0.01% | 1893 |
|
|
2020
Q2 | $543K | Buy |
+6,940
| New | +$459K | 0.02% | 951 |
|
|
2020
Q1 | – | Sell |
-706
| Closed | -$30K | – | 3740 |
|
|
2019
Q4 | $30K | Buy |
706
+672
| +1,976% | +$27.7K | ﹤0.01% | 1661 |
|
|
2019
Q3 | $1K | Sell |
34
-76
| -69% | -$4.13K | ﹤0.01% | 3912 |
|
|
2019
Q2 | $7K | Buy |
+110
| New | +$7K | ﹤0.01% | 2784 |
|
|
2018
Q4 | – | Sell |
-655
| Closed | -$50K | – | 4257 |
|
|
2018
Q3 | $50K | Buy |
+655
| New | +$53.3K | ﹤0.01% | 1765 |
|
|
2018
Q1 | – | Sell |
-1,011
| Closed | -$47K | – | 3728 |
|
|
2017
Q4 | $47K | Sell |
1,011
-1,600
| -61% | -$78.5K | 0.01% | 1381 |
|
|
2017
Q3 | $139K | Buy |
2,611
+2,606
| +52,120% | +$154K | 0.01% | 1056 |
|
|
2017
Q2 | $0 | Buy |
+5
| New | +$301 | ﹤0.01% | 3302 |
|
|
2017
Q1 | – | Sell |
-465
| Closed | -$33K | – | 3755 |
|
|
2016
Q4 | $33K | Buy |
465
+300
| +182% | +$21.3K | ﹤0.01% | 1717 |
|
|
2016
Q3 | $12K | Sell |
165
-104
| -39% | -$6.64K | ﹤0.01% | 1948 |
|
|
2016
Q2 | $13K | Sell |
269
-304
| -53% | -$19.7K | ﹤0.01% | 2597 |
|
|
2016
Q1 | $36K | Buy |
573
+87
| +18% | +$5.69K | 0.01% | 955 |
|
|
2015
Q4 | $55K | Buy |
+486
| New | +$48.6K | 0.01% | 511 |
|
|
2015
Q3 | – | Sell |
-50
| Closed | -$5K | – | 4624 |
|
|
2015
Q2 | $5K | Sell |
50
-58
| -54% | -$4.5K | ﹤0.01% | 3258 |
|
|
2015
Q1 | $7K | Buy |
+108
| New | +$6K | ﹤0.01% | 3066 |
|
|
2014
Q4 | – | Sell |
-27
| Closed | -$2K | – | 4566 |
|
|
2014
Q3 | $2K | Buy |
+27
| New | +$1.36K | ﹤0.01% | 3849 |
|
|
2014
Q2 | – | Sell |
-314
| Closed | -$15K | – | 4532 |
|
|
2014
Q1 | $15K | Buy |
+314
| New | +$16.2K | ﹤0.01% | 2190 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Tower Research Capital (TRC)'s RARE Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Ultragenyx Pharmaceutical (RARE) stake by 110,943% in Q1 2026, buying an estimated $175K and bringing the position to 7,773 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #1785.
Tower Research Capital (TRC) first reported a position in RARE in Q1 2014 and has held it in 40 quarters since. The position peaked at $1.16M in Q2 2021. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Tower Research Capital (TRC) held 7,773 shares of Ultragenyx Pharmaceutical worth $163K as of Q1 2026.
- Tower Research Capital (TRC) bought 7,766 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $175K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1785 holding.
- Tower Research Capital (TRC) first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 40 quarters since.
- Tower Research Capital (TRC)'s Ultragenyx Pharmaceutical position peaked at $1.16M in Q2 2021.
- 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.